JBS NV Ordinary Shares - (JBS) Earnings Date & Reports

Key Takeaways

• JBS swung to a net loss of $102 million in Q2 2026, reversing a $528 million profit from the same quarter last year, driven by non-recurring charges and persistent margin pressure in North American beef.
• Revenue reached an all-time quarterly record of $23.9 billion, up 14% year-over-year and comfortably ahead of the $23.1 billion consensus estimate, reflecting strong global protein demand and higher selling prices.
• Adjusted earnings per share (EPS) came in at $0.20, missing analyst expectations of approximately $0.31 to $0.33, while adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $1.43 billion narrowly topped the $1.42 billion consensus.
• JBS Beef North America posted a negative adjusted EBITDA of $78 million, as record-high live cattle prices continued to outpace beef cutout values, though this marked an improvement from a $233 million loss a year earlier.
• The company paid a $1 billion dividend and announced a CEO transition plan, with Wesley Batista Filho set to succeed Gilberto Tomazoni in January 2027.

Earnings Context and Why It Matters

JBS, the world's largest protein producer, operates a uniquely diversified platform spanning beef, pork, poultry, and value-added products across North America, South America, Australia, and Europe. This Q2 2026 report arrives at a critical juncture: the company is navigating a severe U.S. cattle supply shortage that has squeezed beef margins for multiple quarters, while simultaneously managing softening poultry prices from increased production. The results also carry heightened significance because they mark JBS's first quarterly filing as a U.S. domestic SEC registrant on Form 10-Q, a voluntary transition designed to broaden index eligibility and attract passive investment flows. With 13 of 15 analysts rating the stock a Buy and a mean price target implying roughly 29% upside heading into the print, investor expectations for a margin recovery narrative were high.

Reported Results

JBS reported Q2 2026 net revenue of $23.9 billion, a 14% increase from $21.0 billion in the prior-year period and above the $23.1 billion consensus estimate. The top-line strength was broad-based, with record quarterly sales in JBS Brazil, JBS Beef North America, and the Australia division. However, gross profit contracted to $2.59 billion from $2.83 billion year-over-year, reflecting elevated livestock procurement costs across multiple regions.

The company posted a net loss of $102 million, or $0.10 per share, compared to a profit of $528 million, or $0.48 per share, in Q2 2025. The loss was heavily influenced by non-recurring items, including $172 million in premiums and costs associated with bond and CRA (Certificados de Recebíveis do Agronegócio, or Agribusiness Receivables Certificates) tender offers, and $133 million in antitrust settlement charges. Excluding these items, adjusted net income was $218 million, or $0.20 per share — below the $0.31 to $0.33 consensus.

Adjusted EBITDA under IFRS (International Financial Reporting Standards) declined 18% year-over-year to $1.43 billion, with the margin compressing to 6.0% from 8.4%. Under U.S. GAAP (Generally Accepted Accounting Principles), adjusted EBITDA was $1.257 billion, down 8%. The discrepancy versus consensus expectations was largely attributable to a tougher-than-anticipated poultry pricing environment and continued losses in the U.S. beef segment. JBS Beef North America generated record revenue of $7.77 billion but recorded a negative adjusted EBITDA of $78 million. Pilgrim's Pride, the company's majority-owned poultry subsidiary, saw adjusted EBITDA drop 38.5% to $503 million as elevated industry-wide chicken production pressured prices. In contrast, JBS Brazil delivered record Q2 revenue of $4.59 billion and a 17.8% increase in adjusted EBITDA to $269 million, driven by strong domestic demand and robust exports to China.

AI Screener

For investors seeking to identify opportunities across the protein and broader consumer staples sectors, Tickeron's AI Screener offers a powerful, data-driven solution. The AI Screener is an intelligent stock and ETF discovery tool that enables traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-driven signals. Rather than manually scanning through earnings reports and charts, users can efficiently pinpoint stocks showing bullish or bearish technical formations, breakout candidates, and emerging trends aligned with their strategy. Whether tracking the meat processing industry or broadening into adjacent food and agricultural names, the AI Screener helps surface relevant trade ideas with speed and precision.

Market Reaction and Investor Sentiment

Heading into the August 10 after-market release, JBS shares traded at $14.23, having pulled back considerably from a 52-week high of $18.65. The stock had declined approximately 6% in the trading session prior to the announcement, reflecting cautious positioning. The mixed results — record revenue offset by an earnings miss and a net loss — place the stock in a delicate position. On one hand, the revenue beat and marginally higher-than-expected adjusted EBITDA demonstrate the resilience of JBS's diversified global platform. On the other hand, the adjusted EPS miss and the scale of non-recurring charges may temper enthusiasm. JPMorgan's late-July upgrade to Buy with an $18 price target signaled that institutional sentiment viewed the selloff as overdone, but the earnings release will test that thesis. The $1 billion dividend payout and the CEO succession announcement add layers of complexity to the narrative that investors must digest.

Forward Outlook and Key Factors to Monitor

Looking ahead, several developments will shape JBS's trajectory through the second half of 2026 and into 2027. The most immediate catalyst is the anticipated easing of U.S. cattle import restrictions from Mexico, which the company expects to begin later in August. The U.S.-Mexico cattle border had been constrained by screwworm cases, and a phased reopening could gradually alleviate the livestock supply bottleneck that has plagued North American beef margins. However, the timing means any meaningful financial benefit will likely materialize in subsequent quarters rather than providing an immediate turnaround.

On the poultry side, investors should monitor whether the industry responds to oversupply conditions with production discipline. Pilgrim's Pride's margin compression reflects a broader dynamic where improved bird health, lower avian influenza disruptions, and favorable feed costs have encouraged expanded output — ultimately weighing on chicken prices. Any signal of production cuts or demand recovery in key export markets would be a positive development for segment profitability.

The leadership transition adds another dimension. Wesley Batista Filho, 34, currently leads JBS's U.S. operations and has been the presumed successor to long-time CEO Gilberto Tomazoni. His elevation to global CEO in January 2027 represents a generational shift at the top of the company. Early indications suggest strategic continuity, but the market will closely watch any adjustments to capital allocation priorities, geographic focus, or operational structure under new leadership.

Additional factors to track include the progress of the $2.5 billion joint venture with Indonesia's sovereign wealth fund Danantara, which targets Asia-Pacific protein investments and signals JBS's appetite for geographic expansion. Leverage, which rose to 3.1 times net debt-to-EBITDA from 2.27 times a year earlier, will also remain in focus. While the company boosted total liquidity to $7.7 billion through an expanded revolving credit facility in August, the metric sits slightly above the firm's long-term target range of 2.0 to 3.0 times. How management balances growth investment, shareholder returns, and deleveraging will be a central theme for the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations